

Aric L Gregson

14-154 Warren Hall 957119
University of California
Los Angeles CA 90095
☎ 310-466-2685
☎ 310-825-2591
☎ 310-794-1998
✉ a.gregson@ucla.edu

Education

- 1988–1992 **B.A. with Thesis**, *University of California, Santa Cruz.*
- 1993–1997 **M.D.**, *University of California, School of Medicine, Los Angeles.*
- 1997–1998 **Internship**, *Department of Medicine LAC Harbor-UCLA Medical Center, Torrance.*
- 1998–2000 **Residency**, *Department of Medicine LAC Harbor-UCLA Medical Center, Torrance.*
- 2001–2003 **Clinical Fellowship**, *Division of Infectious Diseases, Department of Medicine, University of Maryland Medical System, Baltimore VA & Shock Trauma, Baltimore.*
- 2003–2005 **Vaccinology Fellowship**, *Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore.*

Licensure

- 1999–present **California**, A68156, Active.
- 2001–2007 **Maryland**, D57097, Inactive.

Board Certification

- 2000–2010 **Diplomate**, *American Board of Internal Medicine Internal Medicine.*
- 2003–2013 **Diplomate**, *American Board of Internal Medicine Infectious Diseases.*

Professional Positions

- 2009–present **Assistant Clinical Professor of Medicine**, *Divisions of Infectious Diseases & General Internal Medicine, Department of Medicine, UCLA School of Medicine, Los Angeles.*
Transplant Infectious Diseases UCLA Heart & Lung Transplant Program; Liver, Small Bowel & Pancreas Transplant Program; Stem Cell Transplant Program.
- 2007–2009 **Assistant Clinical Professor of Medicine**, *Division of Infectious Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles.*
Transplant Infectious Diseases UCLA Heart & Lung Transplant & Cardiac Assist Device Program.
- 2006–2007 **Clinical Instructor of Medicine**, *Division of Infectious Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles.*
Transplant Infectious Diseases UCLA Heart & Lung Transplant & Cardiac Assist Device Program.
- 2005–2006 **Consultant, Clinical Vaccinologist**, *PATH's Malaria Vaccine Initiative, Bethesda.*
RTS,S Program Officer.

- 2002–2005 **Attending Physician & Clinical Instructor**, *Division of Emergency Medicine, Department of Surgery, University of Maryland School of Medicine & Baltimore VA Medical Center*, Baltimore.
Emergency medicine practice & resident teaching in metropolitan VA ED with high acuity.
- 2003–2005 **Attending Physician & Clinical Instructor**, *Division of Geographic Medicine, Department of Medicine, University of Maryland School of Medicine*, Baltimore.
- 2003–2005 **Attending Physician**, *Traveller's Clinic, Department of Medicine, University of Maryland School of Medicine*, Baltimore.
- 2001–2003 **Assistant Clinical Instructor of Medicine**, *Division of Infectious Diseases, Department of Medicine, University of Maryland Medical System*, Baltimore.
- 2000–2001 **Attending Physician**, *Department of Emergency Medicine, Kaiser Permanente West Los Angeles Medical Center*, Los Angeles.
Emergency medicine practice in busy, metropolitan ED with city 911 traffic & high acuity.
- 2000–2001 **Attending Physician**, *Department of Medicine, Kaiser Permanente Bellflower Medical Center*, Bellflower.
Hospitalist on inpatient medical service.
- 2000 **Attending Physician**, *Department of Family Medicine, Kaiser Permanente*, Harbor City & West Los Angeles.
Urgent care.
- 1992–1993 **Emergency Medical Technician-D**, *Long Beach Memorial Medical Center*, Long Beach.
Medical & cardiac intensive care service.
- 1990–1992 **Emergency Medical Technician-D**, *San Benito County EMS*, Hollister.
Emergency ambulance service providing 911 coverage to all of San Benito County.

Professional Activities

- 2012–present **Site Co-Investigator**, *Maribavir/Protocol 1263-202*, UCLA Medical Center & ViroPharma Incorporated, Los Angeles.
A Phase 2, Randomized Study to Assess the Safety and Anti-Cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections that are Resistant or Refractory to Treatment with Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients NCT01611974.
- 2012–present **Site Co-Principal Investigator**, *DEFLECT-1*, UCLA Medical Center & Optimer Pharmaceuticals, Inc, Los Angeles.
A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation NCT01691248.
- 2012–present **Member, Expert Fungal Panel**, *Scientific Council on Infectious Diseases*, International Society for Heart & Lung Transplantation.
- 2012–present **Site Co-Investigator**, *CAPSIL*, UCLA Medical Center & NIH/DMID.
Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R⁺D⁺ Liver Transplant Recipients, NCT01552369.
- 2012–present **Member, Infectious Diseases Management Program**, *UCLA Medical Center*, Los Angeles.
- 2012–present **Associate Editor**, *PLoS Neglected Tropical Diseases*.
- 2012–present **Editorial Board**, *Dataset Papers in Medicine*.

- 2011–present **Infectious diseases outcomes investigations**, *UCLA Medical Center*, Los Angeles.
Utilize hospital-wide data to investigate selective pressure in development of and outcomes for various hospital related infections at UCLA. Initial focus is on VRE blood stream infections in collaboration with Dr. James McKinnell (UCLA-Harbor Infectious Diseases & UCLA CTSI).
- 2010–present **At-Large Representative**, *West Los Angeles Neighborhood Council*, Los Angeles.
- 2008–present **Medical Advisory Committee**, *Fertility Cryobank, LLC*, Los Angeles.
- 2007–present **Academic Editor**, *PLOS ONE*.
- 2007–present **Lung Transplant Executive Committee**, *UCLA Medical Center*, Los Angeles.
- 2007–2009 **Heart Transplant Executive Committee**, *UCLA Medical Center*, Los Angeles.
- 2007–2008 **Immune profiling orthotopic heart transplant recipients**, *UCLA & Stanford School of Medicine*, Los Angeles & Stanford.
Utilize phosphoproteomic-flow cytometry in collaboration with Drs. Daniel Cruz (UCLA Cardiology) & Peter Krutzik (Stanford–Nolan Lab).
- 2006–present **Orthotopic Lung & Heart Transplant Selection Committee**, *UCLA Medical Center*, Los Angeles.
- 2006–present **Translational research within thoracic-organ transplant group**, *UCLA School of Medicine*, Los Angeles.
Collaborative projects focusing on adaptive cellular immune response within lung allografts in response to infection & alloantigen presentation with Drs. John Belperio & Otto Yang.
- 2006–2009 **Department of Medicine Morbidity & Mortality Committee**, *UCLA Department of Medicine*, Los Angeles.
- 2005–2006 **Develop RTS,S phase 2 malaria vaccine trials**, *PATH's Malaria Vaccine Initiative*, Bethesda.
Development of malaria vaccine testing sites throughout Africa, clinical vaccine development plans, trial design & protocol development in collaboration with GSK Biologicals. Interaction with multiple IRBs & DSMBs, & medical safety review of ongoing trials.
- 2002–2004 **Malaria vaccine trial site preparation**, *Center for Vaccine Development (CVD), University of Bamako, WRAIR & GSK Biologicals*, Bandiagara, Mali.
Preparation of phase 1/1b malaria vaccine site in West Africa. Co-investigator involved in trial design, protocol & SOP development, physician training, study initiation & manuscript preparations.
- 2002–2005 **Acting principal investigator phase 1 vaccine trial**, *CVD & DMID*, Baltimore.
Responsibilities included all aspects of trial management from study design, protocol development, SOP & case report form creation, database development, IRB submissions, reporting to DSMB, interaction with funding agency NIAID/DMID, consenting & assessing volunteers, study analysis, reporting trial results at international meetings & writing final manuscript.
- 2002–2003 **Clinical trial site preparation**, *CVD & University of Bamako*, Bancoumana, Mali.
Co-PI on epidemiological study of drug-resistant malaria transmission. Responsible for study design, negotiating collaboration of multiple disciplines in Malian medical school, training of study physicians, analysis of results & presenting at international meetings.
- 2000 **Clinical Malariology**, *Shoklo Malaria Research Unit, Wellcome Trust-Mahidol University*, Mae Sod, Thailand.
Clinical focus on management of malaria and tuberculosis in resource-poor area, brief introduction to malaria field trials.

- 1999 **Clinical Tropical Medicine**, *Programa de Epidemiología y Control de las Enfermedades Tropical (PECET) Universidad de Antioquía & Secretaria de Salud Amazonas*, Medellín, Leticia, Tarapacá, Colombia.
Clinical program in management of tropical diseases and the practice of tropical medicine, with emphasis on malaria, leishmania and endemic fungi.
- 1996 **Epidemiology Elective for Medical Students**, *Centers for Disease Control & Prevention, Hepatitis Division, NCID*, Atlanta.
Investigation of tornado devastation in Arkansas.
- 1996 **Tropical Medicine & Mycology Elective**, *Corporación para Investigaciones Biológicas (CIB)*, Medellín, Colombia.
Clinical introduction to tropical medicine with Drs. Angela & Marcos Restrepo.
- 1996 **Instructor**, *Doctoring IV UCLA School of Medicine*, Los Angeles.
- 1996 **Diagnostic Parasitology Independent Study**, *UCLA Clinical Parasitology Laboratory & UCLA Travel Clinic (Dr. Claire Panosian)*, Los Angeles.

Professional Memberships

- 2010–present **Randonneurs USA**, (#6744).
- 2006–present **American Society of Transplantation**.
- 2006–present **International Society for Heart & Lung Transplantation**.
- 2000–2007 **American Society of Tropical Medicine & Hygiene**.

Ad Hoc Reviewer

Annals of Internal Medicine, Journal of Infectious Diseases, JAMA, Vaccine, American Journal of Transplantation, American Journal of Tropical Medicine and Hygiene, Molecular and Biochemical Parasitology, ACP PIER Modules, Clinical Dermatology.

Honors and Special Awards

- 2011 **Clinical and Health Services Research Award, Junior Faculty**, *Department of Medicine Research Day*.
- 2009 **Visiting Professor**, *Asahi General Hospital*, Asahi, Japan.
Teaching Medical residents Internal Medicine with an emphasis on Infectious Diseases.
- 2005 **Burroughs Welcome Fund-Howard Hughes Medical Institute Course in Scientific Management**, *BWF-HHMI*.
- 2001 **Malaria Research Training Program**, *Center for Vaccine Development, University of Maryland School of Medicine & Fogarty International Center*.
- 1997 **Alpha Omega Alpha, Letter of Distinction in Pediatrics & Doctoring**, *UCLA School of Medicine*.
- 1996 **Marietta Voge Memorial Fund in Tropical Medicine**, *UCLA School of Medicine*.
- 1992 **Phi Beta Kappa, Honors in Biology, College Honors**, *University of California, Santa Cruz*.

Research Grants and Fellowships Received

K23 HL102220 Career Development Award	PI A Gregson, NIH/NHLBI	Active 12/1/10– 11/30/15	“Role of T Regulatory Cells in Preventing Human BOS” Evaluation of intra-graft and circulating lymphocytes and BOS outcomes.
Pilot and Feasibility Award	PI A Gregson, Cystic Fibrosis Foundation	Completed 4/1/10–3/31/12	“Harnessing T Regulatory Cells to Prevent Chronic Lung Allograft Rejection.” Translational lung transplant studies focusing on intra-graft lymphocytes and chemokines.
Stein Oppenheimer Endowment Award	PI A Gregson, Gerald Oppenheimer Foundation	Completed 4/1/10–3/31/11	“Protection Against Development of BOS by CCR7 ⁺ T Regulatory Cells.” Focused evaluation of intra-graft CCR7 ⁺ T _{reg} & BOS outcomes.
T32 AI-07524	PI M Levine, NIH/NRSA	Completed 7/1/01–6/30/06	T32 postdoctoral fellowship training grant, which provided salary support for my fellowship at the CVD.
Fellowship in Tropical Disease Research	PI A Gregson, BWF/ASTMH	Completed 7/1/02–6/30/03	“Burroughs Wellcome Fund-American Society of Tropical Medicine & Hygiene Post-Doctoral Fellowship in Tropical Disease Research”. Research funding and partial salary support for malaria transmission epidemiology study in Mali, West Africa.

Lectures

November 2012	<i>Malaria is Beautiful: Disaster Avoidance for the Clinical Microbiologist</i> , Invited Lecture for the UCLA Clinical Microbiology Laboratory, UCLA Medical Center, Los Angeles.
September 2012	<i>Malaria, Clinical Management</i> , UCLA Division of Infectious Diseases Core Lecture Series, UCLA School of Medicine, Los Angeles.
June 2012	<i>Infectious Prophylaxis Following Lung Transplantation: A Hopeful Journey</i> , Harbor-UCLA Infectious Diseases Grand Rounds, Harbor-UCLA Medical Center, Torrance.
June 2011	<i>Pulmonary Infections Following Thoracic Organ Transplantation</i> , Harbor-UCLA Pulmonary & Critical Care Grand Rounds, Harbor-UCLA Medical Center, Torrance.
May 2011	<i>Phenotypically Distinct T Cell Subsets are Involved in the Pathogenesis of Lung Allograft Dysfunction</i> , UCLA Pulmonary & Critical Care Grand Rounds, UCLA School of Medicine, Los Angeles.
November 2009	<i>Lung Transplantation from the Eye of an Infectious Diseases Doctor</i> , Harbor-UCLA Infectious Diseases Grand Rounds, Harbor-UCLA Medical Center, Torrance.
June 2009	<i>Viral Hemorrhagic Fevers</i> , UCLA Division of Infectious Diseases Core Lecture Series, UCLA School of Medicine, Los Angeles.

- January 2009 ***Malaria, Clinical Management***, *UCLA Division of Infectious Diseases Core Lecture Series*, UCLA School of Medicine, Los Angeles.
- December 2008 ***Clinical Microbiology Review, Part I***, *UCLA Division of Infectious Diseases Core Lecture Series*, UCLA School of Medicine, Los Angeles.
- April 2008 ***Dengue Fever, Clinical Introduction***, *UCLA Division of Infectious Diseases Core Lecture Series*, UCLA School of Medicine, Los Angeles.
- February 2008 ***Unique BALF Effector Lymphocyte Populations Correlate with Lung Allograft Rejection***, *Lung Transplant Core Research Meeting*, UCLA School of Medicine, Los Angeles.
- January 2008 ***Malaria, Clinical Management***, *UCLA Division of Infectious Diseases Core Lecture Series*, UCLA School of Medicine, Los Angeles.
- December 2007 ***Lung Transplantation: From the Eyes of Infectious Diseases***, *Combined Pediatric/Adult Infectious Diseases Grand Rounds*, UCLA School of Medicine, Los Angeles.
- August 2007 ***Malaria: From var to Vaccine***, *Harbor-UCLA Infectious Diseases Grand Rounds*, Harbor-UCLA Medical Center, Torrance.
- June 2007 ***Pulmonary Infections Post-Solid Organ Transplantation***, *Harbor-UCLA Pulmonary Grand Rounds*, Harbor-UCLA Medical Center, Torrance.
- June 2007 ***Tuberculosis***, *UCLA Division of Infectious Diseases Core Lecture Series*, UCLA School of Medicine, Los Angeles.
- March 2007 ***Discussion of Opportunistic Infections in the Setting of Renal Transplantation***, *Division of Nephrology Grand Rounds*, UCLA School of Medicine, Los Angeles.
- March 2007 ***Interesting Infectious Pulmonary Cases***, 5th *UCLA Pulmonary and Critical Care Medicine Update*, Santa Monica.
- February 2007 ***Malaria, Clinical Management***, *UCLA Division of Infectious Diseases Core Lecture Series*, UCLA School of Medicine, Los Angeles.
- October 2006 ***Keynote Speaker***, *Department of Medicine Morbidity & Mortality Conference*, UCLA School of Medicine, Los Angeles.
- June 2006 ***Syphilis: Pathogenesis of Lues***, *Combined Pediatric/Adult Infectious Diseases Grand Rounds*, UCLA School of Medicine, Los Angeles.
- April 2006 ***Malaria var Genes***, *Combined Pediatric/Adult Infectious Diseases Grand Rounds*, UCLA School of Medicine, Los Angeles.
- 2004 ***Phase I trial of a malaria vaccine consisting of hepatitis B virus core particle containing repeat and T-cell epitopes of the P. falciparum CS protein***, *CVD Mini-Presentations, 2004 Frontiers in Vaccinology*, University of Maryland School of Medicine, Baltimore.
- 2003 ***Mosquitoes, Oocysts, Gametes and Us***, *Pathogenesis Conference, Division of Infectious Diseases*, University of Maryland School of Medicine, Baltimore.
- 2002 ***Malaria, the Placenta, and Unpleasant Interactions***, *Pathogenesis Conference, Division of Infectious Diseases*, University of Maryland School of Medicine, Baltimore.
- 2000 ***World Bank and International Health***, *Housestaff Lecture Series Department of Medicine*, LAC Harbor-UCLA Medical Center, Torrance.
- 1999 ***Pheochromocytoma***, *Grand Rounds, Division of Endocrinology, Department of Medicine*, LAC Harbor-UCLA Medical Center, Torrance.

Publications—Research Papers—Peer Reviewed

- [1] Sokolove PE, Lee BS, Krawczyk JA, Banos PT, **Gregson AL**, Boyce DM, Lewis RJ. Implementation of an Emergency Department Triage Procedure for the Detection and Isolation of Patients at High Risk for Having Pulmonary Tuberculosis. *Annals of Emergency Medicine* **2000** Apr; 35(4):327–336. doi:10.1016/S0196-0644(00)70050-3 EF: 0.020 AI: 1.332 JIF: 4.5 Scopus Cites: 11 ISI Cites: 10 Google Scholar Cites: 16
- [2] **Gregson AL**, Plowe CV. Mechanisms of Resistance of Malaria Parasites to Antifolates. *Pharmacological Reviews* **2005** Mar; 57(1):118–145. EF: 0.019 AI: 7.985 JIF: 23.9 Scopus Cites: 128 ISI Cites: 142 Google Scholar Cites: 172
- [3] Thera MA, Doumbo OK, Coulibali D, *et. al.* Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial. *PLoS Clinical Trials*. **2006** Nov 24; 1(7):e34. doi:10.1371/journal.pctr.0010034 Google Scholar Cites: 28
- [4] Thera MA, Doumbo OK, Coulibali D, *et. al.* Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial. *PLoS ONE* **2008** Jan 23; 3(1):e1465. doi:10.1371/journal.pone.0001465 EF: 0.164 AI: 1.918 JIF: 4.6 Scopus Cites: 27 ISI Cites: 32 Google Scholar Cites: 35
- [5] **Gregson AL**, Oliveira G, Othoro Watta C, Calvo-Calle JM, Thorton GB, Nardin E, Edelman R. Phase I trial of Malariavax, a recombinant hepatitis B virus core particle containing repeat and T cell epitopes of the *Plasmodium falciparum* circumsporozoite protein. *PLoS ONE* **2008** Feb 6; 3(2):e1556. doi:10.1371/journal.pone.0001556 EF: 0.164 AI: 1.918 JIF: 4.6 Scopus Scholar Cites: 6 Web of Science Cites: 7 Google Scholar Cites: 10
- [6] **Gregson AL**, Hoji A, Saggarr R, Ross DJ, Kubak BM, Jamieson BD, Weigt SS, Lynch III JP, Ardehali A, Belperio JA, Yang OO. Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. *Transplantation* **2008** Apr 15; 85(7):1056–1059. doi:10.1097/TP.0b013e318169bd85 EF: 0.062 AI: 1.057 JIF: 3.7 Scopus Cites: 14 Google Scholar Cites: 15
- [7] Weigt SS, Elashoff RM, Keane MP, Strieter RM, Gomperts BN, Xue YY, Ardehali A, **Gregson AL**, Kubak B, Fishbein MC, Saggarr R, Ross DJ, Lynch III JP, Zisman DA, Belperio JA. Altered Levels of CC Chemokines during Pulmonary CMV Predict Mortality and Mortality Due to BOS Post-Lung Transplantation. *American Journal of Transplantation* **2008** July; 8(7):1512–1522. doi:10.1111/j.1600-6143.2008.02280.x EF: 0.065 AI: 1.848 JIF: 6.0 Scopus Cites: 14 Google Scholar Cites: 17
- [8] Saggarr R, Ross DJ, Saggarr R, Zisman DA, **Gregson A**, Lynch JP, Keane MP, Weigt SS, Ardehali A, Kubak B, Lai C, Elashoff D, Fishbein MC, Wallace WD, Belperio JA. Pulmonary Hypertension Associated With Lung Transplantation Obliterative Bronchiolitis Is Due To Vascular Remodeling of the Allograft. *American Journal of Transplantation* **2008** July; 8(9):1921–1930. doi:10.1111/j.1600-6143.2008.02338.x EF: 0.065 AI: 1.848 JIF: 6.0 Scopus Cites: 5 ISI Cites: 5 Google Scholar Cites: 7
- [9] Kubak BM, **Gregson AL**, Pegues DA, Leibowitz MR, Carlson M, Marelli D, Patel J, Laks H, Kobashigawa JA. Use of Hearts Transplanted From Donors With Severe Sepsis and Infectious Deaths. *Journal of Heart and Lung Transplantation* **2009** March; 28(3):260–265. doi:10.1016/j.healun.2008.11.911 EF: 0.023 AI: 0.884 JIF: 3.4 Scopus Cites: 3 ISI Cites: 2 Google Scholar Cites: 5

- [10] Nickerson DW, Presson AP, Weigt SS, **Gregson A**, Belperio JA, Gomperts BN. Quantification of cytokeratin 5 mRNA expression in the circulation of healthy human subjects and after lung transplantation. *PLoS ONE* **2009**; 4(6):e5925. doi:10.1371/journal.pone.0005925 EF: 0.164 AI: 1.918 JIF: 4.6
- [11] Weigt SS, Elashoff RM, Huang C, Ardehali A, **Gregson AL**, Kubak B, Fishbein MC, Saggarr R, Keane MP, Saggarr R, Lynch JP, Zisman DA, Ross DJ, Belperio JA. Aspergillus Colonization of the Lung Allograft is a Risk Factor for Bronchiolitis Obliterans Syndrome. *American Journal of Transplantation* **2009** May; 9(8):1903 - 1911. doi:10.1111/j.1600-6143.2009.02635.x EF: 0.065 AI: 1.848 JIF: 6.0 Scopus Cites: 12 ISI Cites: 17 Google Scholar Cites: 21
- [12] Kun H, Moore A, Mascola L, *et. al.*. Transmission of Trypanosoma cruzi by Heart Transplantation. *Clinical Infectious Diseases*. **2009** Jun 1; 48(11):1534–40. doi:10.1086/598931 EF:0.139 AI: 2.575 JIF: 8.2 ISI Cites: 16 Google Scholar Cites: 23
- [13] Wang TF, Wang T, Altman R, Eshaghian P, Lynch JP, Ross DJ, Belperio JA, Weigt SS, Saggarr R, **Gregson A**, Kubak B, Saggarr R. Periostitis Secondary to Prolonged Voriconazole Therapy in Lung Transplant Recipients. *American Journal of Transplantation*. **2009** Oct 21; 9(12):2845–2850. doi:10.1111/j.1600-6143.2009.02837.x EF: 0.065 AI: 1.848 JIF: 6.0 ISI Cites: 5 Google Scholar Cites: 6
- [14] Saggarr R, Khanna D, Furst DE, Belperio JA, Park GS, Weigt SS, Kubak B, Ardehali A, Derhovanessian A, Clements PJ, Shapiro S, Hunter C, **Gregson A**, Fishbein MC, Lynch JP, Ross DJ, Saggarr R. Systemic Sclerosis and Bilateral Lung Transplantation: A Single Center Experience. *European Respiratory Journal*. **2010** Mar 29; 36(4):893–900. doi: 10.1183/09031936.00139809 EF: 0.061 AI: 1.938 JIF: 6.2 ISI Cites: 2 Google Scholar Cites: 3
- [15] Beavogui A, Djimdé AA, **Gregson AL**, Dao A, Maiga H, Fofana B, Coulibaly B, Tekete M, Sacko A, Ouologuem D, Niare O, Kone A, Toure AM, Plowe CV, Doumbo OK. Low Infectivity of Post-Sulfadoxine-Pyrimethamine *Plasmodium falciparum* Gametocytes to *Anopheles gambiae* in Mali. *International Journal for Parasitology* **2010** May 8; 40(10):1213–1220. doi:10.1016/j.ijpara.2010.04.010 EF: 0.020 AI: 1.213 JIF: 3.9 ISI Cites: 2 Google Scholar Cites: 6
- [16] **Gregson AL**, Hoji A, Palchevskiy V, Hu S, Weigt SS, Liao E, Derhovanessian A, Saggarr R, Song S, Elashoff R, Yang OO, Belperio JA. Protection Against Bronchiolitis Obliterans Syndrome is Associated with Allograft CCR7⁺CD45RA⁺ T Regulatory Cells. *PLoS ONE* **2010** Jun 29; 5(6):e11354. 10.1371/journal.pone.0011354 EF: 0.164 AI: 1.918 JIF: 4.6 Web of Science Cites: 3 CrossRef Cites: 3 Google Scholar Cites: 2
- [17] Zaghi D, Panosian C, Gutierrez M, **Gregson A**, Taylor E, Ochoa MT. New World Cutaneous Leishmaniasis: Current Challenges in Diagnoses and Parenteral Therapy. *Journal of the American Academy of Dermatology* **2011** Mar; 64(3):587–592. 10.1016/j.jaad.2009.08.045 EF:0.035 AI:0.84 JIF: 4.2
- [18] Huang HC, Weigt SS, Derhovanessian A, *et. al.*. Non-Tuberculous Mycobacterium Infection after Lung Transplantation is Associated with Increased Mortality. *Journal of Heart and Lung Transplantation* **2011** Jul; 30(7):790–8. 10.1016/j.healun.2011.02.007 EF: 0.023 AI: 0.884 JIF: 3.4
- [19] Weigt SS, **Gregson AL**, Deng JC, Lynch JP, Belperio JA. Respiratory Viral Infections in Hematopoietic Stem Cell and Solid Organ Transplant Recipients. *Seminars in Respiratory and Critical Care Medicine* **2011** Aug; 32(4):471–93. 10.1055/s-0031-1283286 EF: 0.004 AI: 0.66
- [20] Weigt SS, Derhovanessian A, Liao E, Hu S, **Gregson AL**, Kubak BM, Saggarr R, Saggarr R, Plachevskiy V, Fishbein MC, Lynch JP, Ardehali A, Ross DJ, Elashoff RM, Belperio JA.

CXCR3 Chemokine Ligands during Respiratory Viral Infections Predict Progressive Lung Allograft Dysfunction. *American Journal of Transplantation* **2012** Feb; 12(2):477–484. 10.1111/j.1600-6143.2011.03859.x EF: 0.065 AI: 1.848 JIF: 6.0

Publications—Research Papers—Peer Reviewed (in press)

- [1] **Gregson AL**, Wang X, Weigt SS, Elashoff R, Lynch JP III, Ross DJ, Kubak BM, Saggarr R, Ardehali A, Li G, Belperio J. Interaction Between Pseudomonas and CXC Chemokines Increases Risk of BOS and Death in Lung Transplantation *American Journal of Respiratory and Critical Care Medicine*. EF: 1.068 AI: 3.483 JIF: 11.080
- [1] **Gregson AL**, Hoji A, Poynter S, Briones C, Belperio J. Multiparameter Flow Cytometric Characterization of Bronchoalveolar Lavage Lymphocytes for Investigating Post-Lung Transplant Alloimmune Mechanisms *Journal of Visualized Experiments*.

Publications—Research Papers—non-Peer Reviewed

- [1] **Gregson AL**, Wang HH. Aliphatic Alcohols, Local and General Anesthetics and the Nicotinic Acetylcholine Receptor; a Kinetic Binding Analysis to Characterize Ion-Channel non-Competitive Binding Sites. *Senior Thesis*, University of California, Santa Cruz, **1992**.

Publications—Chapters

- [1] **Gregson AL**, Mackowiak PA. Pathogenesis of Fever. In: *Infectious Diseases*, Second Edition, Cohen J, Powderly WG (ed.), Elsevier Limited, Philadelphia, **2004**, p853–859.
- [2] Pegues DA, Kubak BM, Maree CL, **Gregson AL**. Infections in Kidney Transplantation. In: *Handbook of Kidney Transplantation*, Fifth edition, Danovitch GM (ed.), Lippincott Williams & Wilkins, Philadelphia, **2010**, p251–79.
- [3] **Gregson AL**, Mackowiak PA. Pathogenesis of Fever. In: *Infectious Diseases*, Third Edition, Cohen J, Powderly WG (ed.), Elsevier Limited, Philadelphia, **2010**, p673–678.

Publications—Reviews

- [1] **Gregson AL**, Edelman RA. Dengue Virus Infections. *Pediatric Infectious Disease Journal* **2003** Feb; 22(2):179-181. EF: 0.028 AI 1.042 JIF: 3.3 Scopus Cites: 7 ISI Cites: 8 Google Scholar Cites: 9
- [2] **Gregson AL**, Edelman RA. Does Antigen Overload Exist?. *Immunology Allergy Clinics of North America* Vaccines in the 21st Century, **2003** Nov; 23(3):649-664. EF: 0.004 AI 0.877 JIF: 2.7 Scopus Cites: 9 ISI Cites: 9 Google Scholar Cites: 10
- [3] **Gregson AL**. Book Review of Communicable Disease Control in Emergencies: A Field Manual. *Annals of Internal Medicine* **2007** Apr 3; 146(7):544. EF: 0.120 AI: 6.777 JIF: 16.5

Publications—Papers in Preparation (Research Completed)

- [1] **Gregson AL**, Hoji A, Poynter S, Briones C, Palchevskiy V, Weigt SS, Elashoff R, Belperio JA. NK and NT BALF Phenotypes post-Lung Transplantation in Relation to Important Outcome Variables.
- [2] **Gregson AL**, Anene F, Weigt SS, Palchevskiy V, Elashoff R, Belperio JA. Staphylococcus aureus Infection Is Associated with Increased Lung Allograft CXC Chemokines, Not Increased Risk of Death or BOS.

Publications–Abstracts

- [1] Djimdé AA, Toure AM, **Gregson AL**, Beavogui A, Dao A, Maiga H, Fofana B, Coulibaly B, Tekete M, Sacko A, Ouologuem D, Niare O, Kone A, Plowe CV and Doumbo OK. Sulfadoxine-pyrimethamine treatment selects mutant but poorly infectious gametocytes of *P. falciparum* in Kolle, Mali. *NIAID International Centers for Tropical Disease Research*, Eleventh Annual Meeting, **2003**.
- [2] **Gregson AL**, Nardin E, Oliveira G, Othoro-Watta C, Calvo-Calle M, Birkett A, Edelman R. Phase I trial of Malariavax, a recombinant hepatitis B virus core particle containing repeat and T cell epitopes of the *Plasmodium falciparum* circumsporozoite protein. *American Society of Tropical Medicine and Hygiene* 53rd Annual Meeting, Featured Abstract, Abstract #922, 2004 (*American Journal of Tropical Medicine & Hygiene* **2004** Oct; 71(4):S273).
- [3] Djimdé A, Toure AM, **Gregson A**, Beavogui A, Sangare CO, Dao A, Traore Z, Maiga H, Fofana B, Coulibaly B, Tekete M, Sacko A, Ouologuem D, Niare O, Wele M, Plowe CV, Doumbo O. Sulfadoxine-Pyrimethamine treatment reduces malaria transmission in a setting of high Sulfadoxine-Pyrimethamine efficacy of Mali. *American Society of Tropical Medicine and Hygiene* 53rd Annual Meeting, Abstract #112, 2004 (*American Journal of Tropical Medicine & Hygiene* **2004** Oct; 71(4):S34).
- [4] Watta CO, Oliveira GA, Calvo-Calle M, Boehmer G, Kremsner PG, Thornton GB, Edelman R, **Gregson A**, Nardin EH. Human malaria-specific IFN-Gamma T cell responses induced by virus like particles, comprised of hepatitis B virus core antigen and *P. falciparum* circumsporozoite protein T and B cell epitopes (ICC-1132), adjuvanted with alum as compared to ISA 720. *American Society of Tropical Medicine and Hygiene* 55th Annual Meeting, Abstract #1101, 2006 (*American Journal of Tropical Medicine & Hygiene* **2006** Nov; 75(5):S318–319).
- [5] Mossanen M, Cruz, D, **Gregson A**, Krutzik P. Phosphoproteomic Immune Profiling in Orthotopic Heart Transplant Recipients. *American Federation of Medical Research* Annual Meeting, Abstract #339 2008 (*Journal of Investigative Medicine* **2008** Jan; 56(1):216).
- [6] **Gregson AL**, Weigt S, Elashoff R, Yang O, Belperio J. The CCR7 Ligand CCL21 Recruits CCR7⁺ T_{reg} Population to the Lung Allograft that Prevents Development of Bronchiolitis Obliterans Syndrome. *International Society of Heart and Lung Transplantation* 29th Annual Meeting, Featured Abstract, Abstract #144, 2009, Paris. (*Journal of Heart and Lung Transplantation* **2009** Feb; 28(2):S115–116).
- [7] Saggarr R, Belperio JA, Saggarr R, Hunter C, Weigt SS, Lynch JP, Zisman DA, **Gregson A**, Kubak B, Lackey S, Ross DJ, Ardehali A. Intraoperative Versus Postoperative Rabbit Anti-Thymoglobulin Globulin induction for Bilateral Lung Transplantation: A Single Center Randomized Double Blind Placebo Controlled Trial. *International Society of Heart and Lung Transplantation* 29th Annual Meeting, Abstract #684, 2009 (*Journal of Heart and Lung Transplantation* **2009** Feb; 28(2):S303).
- [8] Saggarr R, Saggarr R, Khanna D, Furst DE, Belperio J, Weigt S, Zisman DA, Clements PJ, Ardehali A, Kubak B, **Gregson A**, Lynch JP, Ross D. Systemic Sclerosis and Lung Transplantation: A Single Center Experience. *Arthritis and Rheumatism* **2008** Sep; 58(9):S624.
- [9] DerHovanessian A, Weigt S, Xue Y, Ardehali A, **Gregson AL**, Kubak B, Fishbein M, Saggarr R, Saggarr R, Ross DJ, Lynch JP, Zisman DA, Elashoff RM, Belperio JA. Primary Graft Dysfunction is Associated with BOS and Survival Following Lung Transplantation. *American Thoracic Society* May **2009**.

- [10] Palchevskiy V, Xue YY, Kern R, Weigt SS, Hu S, Derhovanessian A, Song SX, **Gregson A**, Elashoff R, Lynch JP, Belperio JA. The Role of CCR4 during the Pathogenesis of Murine Obliterative Bronchiolitis Post-Transplantation. *International Society of Heart and Lung Transplantation 30th Annual Meeting*, Abstract #394 2010 (*Journal of Heart and Lung Transplantation* **2010** Feb; 29(2):S131).
- [11] **Gregson A**, Wang X, Weigt SS, Elashoff R, Ross D, Kubak B, Saggat R, Ardehali A, Li G, Belperio J. Pseudomonas Infection Increases CXC Chemokines, Risk of BOS and Death in Lung Transplantation. *International Society of Heart and Lung Transplantation 32th Annual Meeting*, Abstract #316, 2012, Prague. (*Journal of Heart and Lung Transplantation* **2012** April; 31(4):S113).